4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright reaffirmed its Buy rating and set a $36 target, implying roughly a 301% upside from the current share price.
• 4D posted an earnings beat—EPS $0.43 vs. -$0.53 expected and revenue $85.09M vs. $30.86M expected—but remains unprofitable with negative margins and is forecast to report -2.84 EPS for the fiscal year.
• Analyst consensus is a Moderate Buy (seven Buys, one Hold, one Sell) with an average price target of $32.71; shares trade around $8.98 (market cap ~$513M) and have a 1‑year range of $2.23–$12.34.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $36.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 300.89% from the stock's current price.

A number of other equities analysts also recently commented on FDMT. Chardan Capital restated a "buy" rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Barclays began coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an "overweight" rating and a $33.00 price objective on the stock. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, December 6th. Royal Bank Of Canada raised their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $32.71.

4D Molecular Therapeutics Trading Up 4.9%

4D Molecular Therapeutics stock opened at $8.98 on Friday. The firm has a market cap of $513.03 million, a P/E ratio of -3.71 and a beta of 2.99. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34. The firm has a 50-day moving average of $8.73 and a 200-day moving average of $9.08.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 33.37% and a negative net margin of 164.43%.The business had revenue of $85.09 million during the quarter, compared to analyst estimates of $30.86 million. Research analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in FDMT. Martingale Asset Management L P boosted its holdings in shares of 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock valued at $88,000 after buying an additional 1,303 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of 4D Molecular Therapeutics by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company's stock worth $504,000 after acquiring an additional 2,069 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of 4D Molecular Therapeutics by 11.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company's stock worth $81,000 after acquiring an additional 2,284 shares in the last quarter. Prelude Capital Management LLC lifted its position in 4D Molecular Therapeutics by 11.1% during the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company's stock valued at $200,000 after acquiring an additional 2,300 shares during the period. Finally, Farther Finance Advisors LLC lifted its position in 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock valued at $43,000 after acquiring an additional 2,674 shares during the period. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.